Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
about
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.Optimizing the use of neoadjuvant endocrine therapy.The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerNeoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancerExpression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.Effect of tamoxifen and raloxifene on the proliferative activity of the breast epithelium in premenopausal women.Clinical development of phosphatidylinositol-3 kinase pathway inhibitorsPresurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer.Letrozole in the neoadjuvant setting: the P024 trial.Controversies in breast cancer: adjuvant and neoadjuvant therapy.Second-line treatment of postmenopausal women with advanced breast carcinoma.A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozolePrimary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.Mammographic breast density response to aromatase inhibition.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinomaOutcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatmentProgression of endocrine therapies for breast cancer: where are we headed?Neoadjuvant/presurgical treatments.Evaluation of biological agents targeted at early-stage disease.Optimizing the implementation of future treatment using surrogate end-points.
P2860
Q27851630-94E8B42D-F505-4E9C-9C52-20475F16E160Q33494720-256C6286-2B48-4FAB-A42B-9363B37CA09EQ33694817-9FDBE5ED-1CEB-4539-A143-7CA69032BFC8Q33710960-341593E5-12B1-4E68-95FB-8458C6AA0303Q33794923-DBDC5EC8-9F66-4135-8A25-2EA9F8FFD84EQ33925038-9E1A1A6A-4349-4A88-BC58-8B01D1476CEEQ33937368-2F93B40B-803F-47A3-B939-B19B2F3BFB5CQ34174466-826D042C-16D8-4B16-9CA4-6A9FC1598A10Q34253719-46089F9C-424F-432A-8861-88F13713C290Q34991926-9C62A1A1-B778-410A-979F-D84B1F669215Q35040111-F17D2868-A624-45F7-9AC4-253CFC29C8F8Q35179983-06637111-BFB5-4883-BD45-0A725B87EF9EQ35566234-95A6B86D-B8F7-4D84-9BC1-6B14ED18792BQ35619082-0AE2C613-3DAC-45C9-9E9E-0A06D930E503Q35681702-69E69103-5BF5-454E-BA93-B3E29D38B8F3Q35826503-96482392-1175-41F5-B375-179A77B99DDBQ35832458-B8D19FFA-835E-407C-BFDA-57EAF101B407Q35875007-CA39C874-BCF6-448A-8AB5-0C8BA370BAC7Q35906326-55D03CAE-3E6F-40E3-B8FA-6C7AD6EAF2A2Q35949304-EC4F9669-A130-4B26-BBD6-6E1B8186AF09Q36026549-9F3FCAD7-09EA-4FE0-A658-7A2A891DAFE7Q36163952-3519C7C3-FA33-4F00-92BA-0FBE9E6ECBD2Q36448699-D130B07C-3C10-4843-AC58-EA302B3951C5Q36507085-10958A9B-DDF1-4B9B-8715-4A0318148B0DQ36614055-4CB3EC57-1EDB-4E47-AB52-6F30EA642211Q36615222-34ED8253-E603-497E-A668-DB8924A7176AQ36615223-83AB6E85-3BD0-4866-A59D-9FE6C7E5802BQ36675384-971B3BF3-5E22-4735-BE01-1D6439BE7037Q36778183-CFCEC16A-2171-497E-AE44-BDBE8FCE6529Q36860992-EB7E9985-F2AB-4677-8C60-978B148DB142Q36903254-B0E63E76-22FD-4131-84E9-39C0B01161A4Q36910400-8E8486D0-087C-4412-AACD-50CF10094ACAQ36916152-750A3167-F0AC-4B6A-A8B9-66B325479873Q36933778-20BB0D79-9789-4083-B834-91CFEC2CBA72Q36977587-BF576111-3A62-4D01-B2FE-92F0D0A8591EQ37003317-3EDDE140-FFD6-4069-8439-AFC1D1FE1830Q37004695-1DC45C05-3AAF-46AF-BF2C-7CE3E118AE43Q37039819-CC808A6D-B60A-498D-9260-FB7E6EBF8BFFQ37039824-0551228F-B08F-499C-9499-AECD334BFF68Q37039828-03A53D43-1439-40B1-81C2-C582CAEF39A2
P2860
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@en
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@nl
type
label
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@en
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@nl
prefLabel
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@en
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@nl
P2093
P356
P1476
Biomarker changes during neoad ...... udy from the IMPACT trialists.
@en
P2093
Anthony Skene
Clive Griffith
Geraldine Walsh
Ian E Smith
Irene Boeddinghaus
J Michael Dixon
Janine Salter
Margaret Hills
Simone Detre
Stephen Francis
P304
P356
10.1200/JCO.2005.07.559
P407
P577
2005-03-14T00:00:00Z